AI-Driven Drug Discovery and Development Collaboration
AI-Driven Drug Discovery and Development Collaboration
Description:
This collaboration with pharmaceutical companies and research institutions uses artificial intelligence and data sharing to accelerate drug discovery and development, focusing on treating prevalent diseases in Abu Dhabi.
Objectives:
• Accelerate the discovery of new drugs and treatments.
• Improve healthcare outcomes through innovative research.
• Support Abu Dhabi’s position as a hub for pharmaceutical innovation.
Socio-Economic Impact:
• Government: Improved healthcare outcomes, reduced treatment costs, and alignment with innovation goals.
• Private Sector: Access to advanced research tools, reduced R&D costs, and enhanced market competitiveness.
Potential Datasets:
• Anonymized Data on disease prevalence and health outcomes.
• Pharmaceutical research data on drug efficacy and patient response.
• Anonymized data on genomic sequences and biomarkers related to disease prevalence.
• Anonymized health records from healthcare providers and hospitals, including medical histories, treatment records, and health outcomes.
Potential Stakeholders:
Pharmaceutical Companies, Biotechnology Firms, and Healthcare Providers and Hospitals.
Code: Health
Sustainable Development Goals (SDG):
International Best Practices:
In the United States, pharmaceutical companies collaborate with the government on AI-driven drug discovery, reducing R&D costs and expediting the availability of new treatments.
How to get involved?
D4G Alliance initiative facilitates win-win collaboration between relevant stakeholders where privately held data are utilized to produce actionable insights for the public interest in the Emirates of Abu Dhabi.
Partner With Us !